Perspective Therapeutics is a pharmaceutical company focused on developing therapies for treating cancer from the inside out. The company aims to create treatments that make a difference for cancer patients and the clinicians who treat them.

Perspective Therapeutics

We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.

Our first human imaging with [203Pb]PSV359 suggests rapid uptake and sustained retention in multiple cancer types. PSV359 is a novel peptide developed by our in-house discovery team which targets Fibroblast Activation Protein-α (FAP).  

Imaging was performed by Dr. Ishita Sen’s group at Fortis Memorial Research Institute - India.

Further information will be available in upcoming presentations and publications.
 
https://lnkd.in/ePh7Z6Zh

#nuclearmedicine #radiopharma #oncology

We're #hiring a new Discovery Lab Organic Chemist in Coralville, Iowa. Apply today or share this post with your network.

Perspective Therapeutics is pleased to announce the appointment of Steve Keefe, MD, MSCE, as Senior Vice President, Clinical Development. 

Dr. Keefe joins us from Merck, where he led global clinical development in gynecologic cancers. His team at Merck was instrumental in advancing groundbreaking therapies, including pembrolizumab, olaparib, and lenvatinib, as well as pioneering combination strategies with earlier-stage compounds.

He received his MD from the University of Chicago and completed a fellowship in Medical Oncology at Penn Medicine. His journey in oncology continued as a clinical investigator at the University of Pennsylvania, where he served on the faculty of the School of Medicine.

We are confident that Dr. Keefe's broad experience in oncology drug development further strengthens our capabilities in bringing our novel radiopharmaceutical medicines all the way to patients and their families. Join us in welcoming Dr. Keefe to the team!

#Radiopharmaceuticals #Oncology

We're excited to be attending the 3rd Annual Targeted Radiopharmaceuticals Summit this week!
Our CBO, Amos Hedt, will be participating in a panel discussion on Wednesday, July 31, and a seminar on Thursday, August 1, focused on the current state and the future of #radiopharmaceuticals.

Learn more at: https://bit.ly/3WrwrcX

Perspective’s CB7-Adma Pre-targeting Platform!

Host -> CB7-conjugated antibody
Guest -> Adma-modified radionuclide
Lag time post Host administration -> Flexible (determined by peak Host tumor uptake and clearance) 

Our best-in-class platform aims to transform a wide range of existing molecules and targets into “radio-ADCs” to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. Revolutionizing cancer treatment with a new breakthrough approach.

https://lnkd.in/eBr3zAT6

We're #hiring a new Executive Administrative Assistant in Coralville, Iowa. Apply today or share this post with your network.

Director of Sales

Brian Berry

Director Isotope Manufacturing

Edwin Sagastume

Director Clinical Operations

Fran Newark

Director of Quality Assurance

Kerri Clifton

Market Development Director

Krista Cline

Director, Upstream Marketing

Nate Culala

Grants and Contracts Manager at Perspective Therapeutics, Inc.

Brad Franzwa

Midwest Regional Sales Manager

Ed Rappel

Human Resources Manager

Jessica Miller

Accounting Manager

Lisa Gerard

Western US Companies (Top 10K)

Health Care Public Companies With Fewer Than 1000 Employees

Western US Companies that Exited (Top 10K)

Seattle Companies With Fewer Than 100 Employees

Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them.

Post-IPO Equity - Perspective Therapeutics

National Institutes of Health

Grant - Perspective Therapeutics

Seattle

Washington

United States

North America

Perspective Therapeutics Inc trading resumes

Perspective Therapeutics a new buy at Wedbush on radiopharmaceutical assets

Perspective Therapeutics’ $80 Million Shares Offering

Perspective therapeutics CEO buys $117k in company stock By Investing.com

Perspective Therapeutics CEO buys $117.4K in common stock

Perspective Therapeutics to implement reverse stock split

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Perspective Therapeutics, Bristol Myers Squibb partner to evaluate drug combo for skin cancer

Perspective Therapeutics sells subsidiary to Arizona company

United Kingdom

Europe

Philippines

Asia

Israel

Canada

HTML5

F5 NGINX

Google Tag Manager

jQuery

Wordpress

Google Compute Engine

Google Analytics

Bootstrap

Google Fonts

Google Drive

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Perspective Therapeutics, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 5, 2024 2:44 PM	4fef0cc9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:50 PM	1acd694e
crunchbase profile	general	Oct 28, 2024 3:17 PM	18272bbe
li profile	general	Aug 5, 2024 2:44 PM	c156c3f4
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	dd3812c7
peers	general	Aug 5, 2024 2:44 PM	5d1650e1
news basic	general	Aug 5, 2024 2:44 PM	70ffe652
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:PERSPECTIVETHERAPEUTICS

Perspective Therapeutics

Last Close

3.00

22/11 21:00

Market Cap

234.53M

Beta: -

Volume Today

9.18M

Avg: -